Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science Angel Investors in United States

Last updated: Jul 2024 A list of 50 angel investors that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.

Top 50 Life Science Angel Investors in United States

Investor	Life Science United States investments
Sahin Boydas	5
Milad Alucozai	4
bumpkins profile	4
Darian Shirazi	3
Chris Gibson	3
Erik Peterson	3
Esther Dyson	3
Kevin Moore	3
Peter Harris	2
Joshua Elkington	2
Brian S. Cohen	2
CJ Reim	2
Kevin Mahaffey	2
David R. Walt	2
Sujay Jaswa	2
Kathryn Haun	2
Patrick Collison	2
Nat Turner	2
Craig Mundie	2
Lars Fjeldsoe-Nielsen	2
Mei Z.	2
Ankit Jain	2
Michael Chambers	2
Patrick Yang	2
Zach Weinberg	2
James Hong	2
Elad Gil	2
Jay Zaveri	2
Vinny Lingham	1
Alice Zhang	1
Chuck Farkas	1
Jeff Raikes	1
Haig Farris	1
Noel Hall	1
Avichal Garg	1
Haig Farris	1
Joe Beverly	1
Daniel Goldman	1
Nimi Katragadda	1
Douglas Hansen	1
Dilek Dayinlarli	1
Paul Manning	1
Jim Greer	1
Willard Umphrey	1
Timothy A. Springer	1
Scott Garber	1
Leonardo DiCaprio	1
Jonathan Milner	1
Julia Popowitz	1
Elliott Sigal	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Sahin Boydas is the Head of RemoteTeam at Gusto.

Investment focus

Software, Financial Services, FinTech
Seed, Series A, Series B
United States, Mexico, Spain

Portfolio highlights

Valur — Tax planning with Valur is the easiest way to reduce your taxes on capital gains, ordinary income, carried interest, and more. Create a tax plan today!
Heyday AI — Manage all your social media messages in one place, including private messages and comments, with Hootsuite. Clean up your inbox with a free trial now!
MULTI·ON — We are a technology and design group exploring novel ways to use AI to expand what people are capable of.

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Pre-Seed
United States, Canada, United Kingdom

Portfolio highlights

Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.

blah - teh software was teh busted and they didn't want to fix it or hire someone to fix it, odd folks, these.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Pre-Seed
United States, Canada, India

Portfolio highlights

Sorare — Global Fantasy Football. Collect limited edition digital collectibles, Manage your team and earn prizes!
Hoth Intelligence — Hoth Intelligence home page. Space age surgical technology brought down to earth.
Floating Point Group — Floating Point Group is a trading platform provider offering innovative, industry-leading trade execution and settlement

Darian Shirazi is the General Partner of Gradient Ventures.

Investment focus

Software, Information Technology, SaaS
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Medmo — Medmo is an all-encompassing solution for providers to order, schedule, and track medical imaging appointments for their patients. Improve completion rates with less staff burden and lower costs.
Resend — Build, test, and send transactional emails at scale.
Infisical — Infisical is an open-source, end-to-end encrypted tool that supports developers in managing their teams, devices, and infrastructure's secrets and environment variables. Using an end-to-end encrypted method, it avoids the leakage of confidential information to version control and over insecure channels like email.

Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Seed
United States, France, Switzerland

Portfolio highlights

Amenities Health — Discover your dedicated Digital Front Door platform that enhances the patient experience and foster brand loyalty.
Cradle — Design better proteins
Leash Biosciences — We're transforming drug design with a rich dataset built by screening millions of compounds against thousands of protein to generate billions of data points, ideal for training advanced machine learning models.

Erik Peterson is the Founder at DormTrader.

Investment focus

Software, Biotechnology, SaaS
Seed, Equity Crowdfunding, Series A
United States, Canada, Algeria

Portfolio highlights

Hideout — Hideout makes high-quality food that is available for delivery. Danielle Sobel established the company in Los Angeles, California.
Abalone Bio — Our Functional Antibody Selection Technology platform (FAST) taps into the potential of the body's biological activities, expanding the reach of antibody drugs.
Altay Therapeutics — Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions. It is currently focused on finding curative therapies for fibrosis, NASH, and liver cancer. It develops novel small molecule drugs against transcriptional regulators that are validated drivers of disease. It wasfounded in 2019 and is headquartered in San Francisco, California.

Esther Dyson - Founder @ Way to Wellville

Investment focus

Health Care, Software, Medical
Seed, Series A, Funding Round
United States, Canada, Russian Federation

Portfolio highlights

Ezra AI — Ezra provides full-body MRI screening for potential early cancer and abnormalities in up to 13 organs. Book a scan today.
Boxhub — Buy new & used shipping containers with Boxhub. We make buying a shipping & storage containers easy - get it delivered right to your door. Shop today!
Way — Way combines intuitive eating with behavior science for mindful habits. 73.5% of app users report transformed thinking post-program.

Kevin Moore has 10 years experience as an angel/opportunity investor and operator. Prior to that, he has over 15 years of progressive technology i-banking, corp dev, and CFO experience at startups and $Bn corporates.

Investment focus

Software, Health Care, E-Commerce
Seed, Pre-Seed, Angel
United States, India, Canada

Portfolio highlights

Redbird — Redbird is an operating system that empowers data driven teams to easily create custom applications that automate advanced analytics work in minutes, without writing code.
SilkChart — SilkChart helps growth teams improve campaigns based on what users are doing in product - without relying on expensive data scientists. We do this through a no code analytics tool that combines marketing and product usage data to identify which channels, audiences, and content maximize revenue growth.
Augmend — Record your screen. Capture knowledge. Scale your expertise and yourself. Record once, share forever.

Peter Harris

Investment focus

Life Science, Biotechnology, Health Diagnostics
Seed
United States

Portfolio highlights

CND Life Sciences — Our suite of neurodiagnostic tests give clinicians access to objective pathological insights on diseases that are often difficult to diagnose

Joshua Elkington

Investment focus

Biopharma, Life Science, Biotechnology
Seed
United States

Portfolio highlights

Tierra Biosciences, Inc. — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.
Tierra Biosciences — Speed, scale and simplicity with protein synthesis on-demand. Discover your portal to thousands of custom proteins. Get testable material with a single input.

Considered one of the fathers of science & technology strategic communications - founded Technology Solutions, Inc. in 1983. Client list read like a who's who list of startup technology companies in computing, communication, software, education, and entertainment. Maintained a strategic communications partnership with Sony & IBMCorporation (10 years). Received the Gold CIPRA award in 1998 for the IBM Deep Blue/Gary Kasparov Chess Match. In 1996, TSI was recognized as the #1 fastest growing agency in the United States. Sold the company to The McCann Erickson World Group in 1997 and became the Vice Chairman. Created Focus Technology, an organization that provided qualitative research and instituted the RPM model of integrated strategic communications providing ultra-competitive technology clients the ability to quickly discover and leverage their key strengths as well as mitigate their destructive weaknesses.Brian was a pioneer in the founding of a number of the first computing publications including Computer Systems News and InformationWeek magazine. Now serves as Chairman of the New York Angels. He is very devoted to the New York City startup community.Developed the AIMS (Applied Internet Media Studies) Program, a senior/graduate level college semester program where students will be rigorously trained to use the internet professionally.Frequent speaker on strategic communication, entrepreneurism and early startup investing. Now writing a book for McGraw Hill - a new organizational product launch model.Received the Distinguished Alumnus Award, holds a Masters Degree in Science Communications from Boston University's School of Communications.

Investment focus

Software, SaaS, Mobile
Seed, Series A, Funding Round
United States, Israel

Portfolio highlights

Authorea — Authorea is a provider of a collaborative platform that is designed to read, write, discuss, and publish research. Its platform serves as a powerful document editor for researchers and provides collaborative editing, automatic citation formatting, tracking changes and it has the ability to make any document public or fully private that enablesresearchers to write documents together and attach references, figures, data, and source code. It improves how researchers work and make breakthrough discoveries by tackling one of the most important parts of the research cycle which is communication.
CourseHorse — CourseHorse is a provider of a learning platform used to centralize the learning opportunities. Its platform partners with providers of Spanish lessons, cooking courses, yoga classes, and other classes to create a single destination for people seeking personal interest education that enables people to increase ease and confidence in discovering thepath to personal enrichment.It was founded in 2011 and is headquartered in New York.
Boundless Mind — Thrive Global's mission is to end the burnout epidemic with sustainable, science-based solutions that unlock employee performance and enhance well-being through our behavior change technology.

CJ Reim is a co-founder of Amity Ventures and an active investor in Avochato, Carta, Ouster, Talkdesk, and more than 15 other growing technology businesses. CJ is currently focused on investments in software, fintech, and consumer sectors, and represents Amity on the boards of Avochato and MaintainX.Prior to Amity, CJ was a Vice President on theinvestment team at Highland Capital Partners, where he focused on technology investments across all stages of company growth. He also led the Summer@Highland entrepreneurship program which, over its nine-year history, has mentored 50 student-led startups from inception. CJ is originally from Minnesota and holds a B.S. in Management with concentrations in Finance and Information Systems from Boston College. Outside of Amity, CJ enjoys CrossFit, freediving, and downhill skiing.

Investment focus

Robotics, E-Commerce, Internet
Series A, Seed, Series B
United States

Portfolio highlights

Athelas — Our breakthrough technologies provide clarity on a patient's most important health metrics, all while increasing revenue for your practice.
Burrow — Meet Burrow. We make clever, uncompromising furniture and other nice things fit for modern life at home. From our comfortable, customizable sofas, sectionals, loveseats, and armchairs to our fashionable, functional rugs and tables, and five unique collections of decorative pillows and throw blankets, Burrow is the perfect place to start when shopping for your home.
Arkive — Arkive is a web3 museum of real world items, curated by a community of passionate hobbyists, collectors, artists, designers, and creators.

Kevin Patrick Mahaffey is the Founder of Lookout and SNR. He is also the Executive Chairman of Stork Club and an Investor.

Investment focus

Software, SaaS, Enterprise Software
Seed, Series A, Pre-Seed
United States, Canada, Israel

Portfolio highlights

Knostic — Knostic provides need-to-know access controls for Large Language Models (LLMs). Its knowledge-centric capabilities enable enterprises to expedite the deployment of LLMs and drive AI-powered innovation while maintaining value, security, and safety.
bem — Engineering teams use bem to transform any data point into whatever shape they need.
Token Security — Token is the new approach designed for the identity boom era. Introducing Machine-First Identity Security.

David is Professor in the Department of Pathology, Brigham and Women’s Hospital and Wyss Institute for Biologically Inspired Engineering, and is a Howard Hughes Medical Institute Professor. David is the Scientific Founder of Illumina Inc. and Quanterix Corp and has co-founded several other life sciences startups. David has published over 300peer-reviewed papers and has over 75 issued US patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical microwell arrays and single molecules including the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, Ralph Adams Award in Bioanalytical Chemistry, the American Chemical Society Gustavus John Esselen Award, Analytical Chemistry Spectrochemical Analysis Award, the Pittsburgh Analytical Chemistry Award, and the ACS National Award for Creative Invention. He is a member of the National Academy of Engineering, the National Academy of Medicine, a Fellow of the American Academy of Arts and Sciences, a Fellow of the American Institute for Medical and Biological Engineering, and a Fellow of the National Academy of Inventors. He received a BS in Chemistry from the University of Michigan and a PhD in Chemical Biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.

Investment focus

Biotechnology, Genetics, Life Science
Seed, Series A, Series B
United States

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
Stoicheia — Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creatingstructures comprising up to seven elements.
Torus Biosystems — Torus Biosystems offers an apparatus for DNA testing for scientific and medical research purposes in the fields of consumer products, food for human beings or animals, hygienic and beauty care for human beings or animals, agriculture, horticulture, and forestry. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Sujay Jaswa is founder and managing partner at WndrCo, a holding company that invests in and acquires consumer technology businesses. He serves as Chairman of Aura, Twingate, VPN Super, and is a Director of The Infatuation. Board member of Vy Global Growth (Nasdaq: VYGG). Advisor at Seven1 Sports & Entertainment Agency. He is also a lecturerat the Stanford Graduate School of Business. He formerly served as business founder, vice president of business, and CFO of Dropbox from 2010 to 2015. At Dropbox, Sujay created and led the global business and finance organization. He has a Bachelor’s degree in Economics from Princeton University and an MBA from Harvard Business School.

Investment focus

Software, FinTech, Financial Services
Seed, Series B, Series A
United States, Spain, Germany

Portfolio highlights

HUBUC — A single API-platform that allows any business to embed financial services capabilities into their products.  e.g Uber can issue branded credit cards for all Uber drivers and Walmart provides customers a simple way to better manage and control their everyday finances, with no regulatory burden or compliance requirements in a few weeks.
point.me — Stop wasting your points! Find the best flight deals with the fewest points and make your dream trip a reality. Start your first search for free today!
Fireside — Fireside is the first interactive streaming platform that invites you to be part of the show. Co-founded by Falon Fatemi and Mark Cuban the media and entertainment networks of the future are emerging on Fireside.

Katie Haun is a General Partner at Andreessen Horowitz. She serves on the boards of Coinbase and HackerOne and has invested in and advised tech companies from seed to Series E stage. Katie teaches a management course at Stanford Business School and previously taught cybercrime at Stanford Law School. Previously, she spent a decade as a federalprosecutor with the U.S. Department of Justice focusing on fraud, cyber, and corporate crime alongside agencies including the SEC, FBI, and Treasury. She created the government’s first cryptocurrency task force and led investigations into the Mt. Gox hack and the corrupt agents on the Silk Road task force. She also prosecuted RICO murders, organized crime, public corruption, gangs, and money laundering, and held senior policy positions at headquarters in both the National Security Division and Attorney General’s office where her portfolio included antitrust, tax, and national security. Katie clerked for U.S. Supreme Court Justice Anthony Kennedy and is an honors graduate of Stanford Law School.

Investment focus

Blockchain, Financial Services, FinTech
Funding Round, Seed, Series A
United States, United Kingdom

Portfolio highlights

dub — The first Copy-Trading platform for stocks. Copy anyone's investments. For free. Regulated Broker-Dealer member FINRA and SIPC & FDIC insured.
Aptos — Building products, applications, and tooling on the Aptos blockchain. Bringing the benefits of decentralization to the masses.
Primer — Primer is the world's first community built for curious and ambitious kids to find and explore their interests together.

Patrick Collison is a Content Strategist for Stripe.

Investment focus

Software, Financial Services, Information Technology
Seed, Series A, Series C
United States, United Kingdom, India

Portfolio highlights

Matic — The world's most advanced floor cleaner. Your home's best helper.
Cognition — Cognition is an applied artificial intelligence lab that focuses on reasoning and code.
The Bot Company — The Bot Company a household robot startup.

Before co-founding Flatiron, Nat was Co-Founder and CEO of Invite Media, an advertising technology company based in NYC. Invite Media built the industry's first enterprise advertising platform for buying and optimizing online media in real-time. Invite Media was acquired by Google in 2010. Prior to Invite Media, Nat started numerousinternet companies and also worked at Say Media and First Round Capital. An active angel investor, Nat has invested in over 30 technology startups throughout the country, including Bell Biosystems, Breakthrough, Care at Hand, DocPhin, Doctor Evidence, Genomera, Meddik, Oscar, and Predilytics. Nat earned a Bachelor of Science degree cum laude in Economics with concentrations in Entrepreneurship and Marketing from The Wharton School of the University of Pennsylvania. In his spare time, Nat is an avid golfer and tries to trick trout with fake bugs.

Investment focus

Health Care, Software, Medical
Seed, Series A, Series B
United States, China, Colombia

Portfolio highlights

CollX — Snap photos of them and instantly get the current market price. Add them to your collection and track your overall portfolio value.
Collectors — Helping collectors to pursue their passion.
Iterative Scopes — Iterative Scopes provides gastroenterologists with machine learning-powered diagnostic tools that help them prevent colon cancer and improve patient outcomes

Craig Mundie is chief research and strategy officer of Microsoft Corp., reporting to CEO Steve Ballmer. In this role, he oversees Microsoft Research, one of the world’s largest computer-science research organizations, and is responsible for Microsoft’s long-term technology strategy. Mundie also directs a number of technology incubations, and workswith government and business leaders around the world on technology policy, regulation and standards.Mundie has spent much of his career building startups in various fields, including supercomputing, consumer electronics, education, healthcare and robotics. He joined Microsoft in 1992 to create and run the Consumer Platforms Division, which developed non-PC platforms such as the Windows CE operating system; software for the Handheld PC, Pocket PC and Auto PC; and early console-gaming products. Mundie also started Microsoft’s digital-TV efforts, acquiring and managing its WebTV Networks subsidiary, and built its fast-growing healthcare solutions business.Prior to his current role, Mundie served as Microsoft’s chief technical officer for advanced strategies and policy, working with Microsoft Chairman Bill Gates to develop the company’s global strategies around technical, business and policy issues. Another long-standing focus for Mundie is privacy, security and cyber-security. He initiated Microsoft’s Trustworthy Computing initiative, which has leveraged new software-development practices to significantly improve the security of the company’s products.For more than a decade, Mundie has also been Microsoft’s principal technology-policy liaison to the U.S. and foreign governments, with an emphasis on China, India and Russia. He has served on the U.S. National Security Telecommunications Advisory Committee and the Markle Foundation Task Force on National Security in the Information Age. In April 2009 Mundie was appointed by President Barack Obama to the President’s Council of Advisors on Science and Technology.Mundie started his career in 1970, working on operating-system development for the Data General NOVA at Systems Equipment Corp. (SEC) while still studying at Georgia Tech. SEC was subsequently acquired by Data General Corp., where Mundie went on to develop the INFOS data-management system. In 1977 Mundie moved to Data General’s advanced development facility in Research Triangle Park, N.C., ultimately becoming its director. In 1982, Mundie was one of three co-founders of Alliant Computer Systems Corp., which developed vector-parallel mini-supercomputers. He held a variety of positions at Alliant before becoming CEO. The company shut down in 1992.Mundie holds a bachelor’s degree in electrical engineering and a master’s degree in information theory and computer science from Georgia Tech. Mundie enjoys traveling and spending time on his boat. He is married, with one married daughter.

Investment focus

Life Science, Chemical, Genetics
Seed, Series B, Series C
United States

Portfolio highlights

Stoicheia — Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creatingstructures comprising up to seven elements.
Exicure — Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Lars Fjeldsoe-Nielsen is a Co-Founder & serves as a Partner at 2xN. Lars Fjeldsoe-Nielsen was General Partner at Balderton Capital in London from 2015-2021 through four funds. He joined after spending a decade in Silicon Valley where he was with Uber and Dropbox.Since 2012 his venture track record includes two IPOs (Uber, Dropbox) and 11acquisitions.Lars joined Balderton from Uber which he joined when the company was operating in less than 20 cities. His role as Vice-President resulted in strategic alliances. Lars joined Uber from Dropbox as one of the company’s first 25 employees. As Head of Mobile, his growth deals with Samsung and other mobile OEMs helped Dropbox reach its first 100 million users. Prior to that Lars held positions at Voicesignal (acq. Nuance), Skyhook Wireless (acq. TruePosition), Ness Technologies (acq. Opentable), 3Jam (acq. Skype) and T9 Tegic (acq. AOL). More than a billion people have used the software and services distributed as a result of mobile growth partnerships led by Lars.His venture investments include Voi (Raine), Labster (A16Z), Hiya (Ericsson), Cambridge Quantum Computing (HON), Hopin (A16Z), Opensea (A16Z), Yassir (YC), Beacon (Eric Schmidt), The org (Sequoia), Octant (A16Z), Zycada (Khosla), Monarch Money (Accel) and Kukua (Tencent), Dubsmash (acq. Reddit), Tempow (acq. Google), Rahko (acq. Odyssey Therapeutics), Pocket (acq. Mozilla), Blue Bottle (acq. Nestle), Marble (acq. Caterpillar).Lars, who is Danish-Portuguese, grew up across Africa and served with the Royal Danish Guards. He holds a MBA from London Business School, where he also serves on the Board of Trustees, an MSc from Oxford University Keble College and a BSc from King’s College, London. He lives in London with his wife and three children.

Investment focus

Software, Information Technology, Mobile Apps
Seed, Series A, Funding Round
United States, Denmark, United Kingdom

Portfolio highlights

HUBUC — A single API-platform that allows any business to embed financial services capabilities into their products.  e.g Uber can issue branded credit cards for all Uber drivers and Walmart provides customers a simple way to better manage and control their everyday finances, with no regulatory burden or compliance requirements in a few weeks.
LiveFlow — The easiest way to bring financial data into your spreadsheet. Automate your finances, consolidate your accounts and collaborate in real-time. Try LiveFlow for free today!
Quantrol Ox — QuantrolOx is building automated machine learning-based control software for quantum technologies to tune, stabilize, and optimize qubits.

Mei Z. is the Co-Founder and Partner at Alloy Fund. Mei was a Former Associate at Romulus Capital, and studied at Massachusetts Institute of Technology.

Investment focus

Biotechnology, FinTech, Software
Seed, Series A, Pre-Seed
United States, United Kingdom, Singapore

Portfolio highlights

Cube AI — Cube AI boosts back-office logistics efficiency, allowing teams to handle more loads and focus on human relationships.
SynthLabs — research lab for transparent, auditable AI alignment
Essential AI — Essential AI aims to build software for enterprises to use large language models, the core software of a new artificial intelligence system.

Ankit Jain is the Founder and CEO of Infinitus Systems.

Investment focus

Health Care, Medical, Hospital
Seed, Pre-Seed
United States

Portfolio highlights

RapidClaims — Rapid Claims helps businesses autonomously code medical charts, find up-coding opportunities, improve the CDI process and reduce denials.
Empower Sleep — Empower Sleep provides personalized sleep care online
Resilient Lifescience — Resilient Lifescience is developing a wearable medical device to detect and reverse opioid overdose

Michael Chambers is the Co-Founder at Agathos Biologics.Michael’s vision and leadership of Aldevron has resulted in several milestones including the 2004 acquisition of Genovac Antibody Technology of Freiburg, Germany; the 2009 expansion of protein production in Madison, Wisconsin; private equity transactions by TA Associates in 2017 and EQT in2020; and the purchase of Aldevron by Danaher for $9.6 billion in 2021. Michael is committed to ethical pharmaceutical development and his leadership will enable Agathos to create new paradigms in biotechnology to achieve these goals. Michael received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from North Dakota State University.

Investment focus

Biotechnology, Genetics, Life Science
Series A, Funding Round
United States

Portfolio highlights

Kytopen — Kytopen is pioneering a novel and non-viral process to engineer human cells for therapeutic applications in immuno-oncology and genetic disorders.
Erbi Biosystems — Erbi Biosystems is a transformative microfluidic bioprocess instrumentation company.
64x Bio — 64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery.The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specificfocus on those used for cell and gene therapies.

Patrick Yang, General Partner at Amity Ventures, has led the firm’s investments in CaptivateIQ, Evisort, Flick, MoQuality, TruePill, and Vowel. He sits on the boards of Evisort and MoQuality. His primary areas of investment focus include AI, consumer, logistics, mobility, and software. Patrick co-founded Amity Ventures with CJ Reim in 2017 afterthe two worked together at Highland Capital Partners.Prior to Amity, Patrick was a Vice President at Highland, where he sourced the firm’s investment in nuTonomy, an autonomous vehicle startup acquired by Delphi one year later for $450M. Patrick is from the Bay Area and holds a B.S. in Business Administration with a concentration in Engineering Leadership from University of California, Berkeley.Pat currently serves on the board of Advancing Women in Product, a non-profit that empowers women to enter and succeed in product management roles. In his free time, he enjoys hiking and eating in the San Francisco area, and attending sporting events—especially Warriors, 49ers, and Giants games.

Investment focus

Software, E-Commerce, Health Care
Series A, Seed, Series B
United States

Portfolio highlights

Athelas — Our breakthrough technologies provide clarity on a patient's most important health metrics, all while increasing revenue for your practice.
Burrow — Meet Burrow. We make clever, uncompromising furniture and other nice things fit for modern life at home. From our comfortable, customizable sofas, sectionals, loveseats, and armchairs to our fashionable, functional rugs and tables, and five unique collections of decorative pillows and throw blankets, Burrow is the perfect place to start when shopping for your home.
Innerwell — Innerwell combines personalized guidance from licensed therapists like you with the expansive power of psychedelics to treat anxiety and depression.

Before co-founding Flatiron, Zach was Co-Founder, President and COO of Invite Media, an advertising technology company based in NYC. Invite Media built the industry's first enterprise advertising platform for buying and optimizing online media in real-time. Invite Media was acquired by Google in 2010. Prior to Invite Media, Zach co-foundedEatNow.com which was privately acquired. An active angel investor, Zach has invested in over 30 technology startups throughout the country, including Bell Biosystems, Breakthrough.com, Care at Hand, DocPhin, Doctor Evidence, Genomera, Meddik, Oscar, and Predilytics. Zach studied economics and entrepreneurship at The Wharton School at the University of Pennsylvania.

Investment focus

Health Care, Software, SaaS
Seed, Series A, Pre-Seed
United States, Israel, United Kingdom

Portfolio highlights

Scoop — Thrive in a hybrid work environment with Scoop's solutions for Workplace Safety, Workplace Utilization, Team Coordination, Desk Management, and Commute.
Iterative Scopes — Iterative Scopes provides gastroenterologists with machine learning-powered diagnostic tools that help them prevent colon cancer and improve patient outcomes
Overwatch Research — Generate accurate in vivo study data as a part of your efficient, connected R&D.

James Hong

Investment focus

E-Commerce, Software, Internet
Seed, Series A, Angel
United States

Portfolio highlights

Athelas — Our breakthrough technologies provide clarity on a patient's most important health metrics, all while increasing revenue for your practice.
Deep Infra — Deep Infra offers cost-effective, scalable, easy-to-deploy, and production-ready machine-learning models and infrastructures for deep-learning models.
Alchemy — Whether you're a beginner, working on a side project, or one of the largest teams in the blockchain space, Alchemy makes Ethereum development easy with enhanced APIs, node infrastructure, and developer tooling. Get started for free!

Elad Gil is the Co-Founder of Color Genomics. He previously worked at Twitter as a Vice President. Elad Gil attended the Massachusetts Institute of Technology.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Series B
United States, United Kingdom, Israel

Portfolio highlights

Ashby — Ashby is a developer of recruitment software used for high-growth companies. It develops usable, enterprise-grade employment software that enables company leaders, recruiters, and hiring managers to run their hiring process significantly better. It was founded in 2018 and is based in San Francisco, California.
Pika — The idea-to-video platform that sets your creativity in motion.
Decagon — Trusted by world-class companies, Decagon is the most advanced AI platform for customer support.

Jay Zaveri has been serving Social Capital as a partner since November 2015. He also founded CloudOn and Future Thought Productions.

Investment focus

Biotechnology, Health Care, Artificial Intelligence
Seed, Series A, Funding Round
United States, Japan, Canada

Portfolio highlights

Cleerly — Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.
BitClout — BitClout is a platform owned by its users. Bitcoin is decentralizing money, BitClout is decentralizing social media.
Kingdom Supercultures — Kingdom Supercultures create microbial cultures that help food manufacturers to create new foods with boosted benefits. It re-assembles nature's microbes into new combinations, creating plant-based foods that taste like dairy, low-alcohol beverages with full flavor, and natural preservatives that work as well as artificial ones.They workwith clients across diverse industries including food, beverage, personal care, beauty, and more. Their technology comprises an expansive biobank of GRAS microbial strains, high-resolution strain characterization, and new algorithms for predicting and assembling microbial communities.

Vinny Lingham is Co-Founder & CEO at Civic. He was the founder and CEO of Gyft, a mobile gift card app that allows customers to buy, store, send and redeem gift cards conveniently from their mobile device. He is also the founder of Yola.com, a web development and hosting company that enables users without prior programming knowledge to developwebsites. Vinny is the recipient of numerous awards, including Top Young ICT Entrepreneur in Africa (2006) and was also a finalist for Men’s Health Best Man (2009) and ICT Personality of the Year in South Africa (2008). He also previously founded Clicks2Customers, which also won the Top Technology Company award in South Africa in 2006. He has previously served on marketing advisory boards for Nasdaq listed Valueclick and Yahoo, was also selected as an Endeavor “High Impact Entrepreneur” in 2006. Vinny studied a B.Com (Information Systems) at the University of Cape Town.

Investment focus

Blockchain, Internet, Cryptocurrency
Seed, Funding Round, Angel
United States, South Africa, United Kingdom

Portfolio highlights

TipLink — TipLink helps send crypto with a link. Someone with crypto can create a account and send that link to anyone over any platform. It’s like buying a gift card, connect the client's crypto wallet of choice and create a account by depositing how much they want to send.
Afterparty — Your favorite creators are here! Get 1 on 1 unfiltered experiences with creators through Afterparty livestreams or chat 24/7 through AI powered conversations
Collectibles.com — Collectibles.com is a Web3 community and marketplace for collectors and the worldwide collectibles sector.

CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Pre-Seed
United States, United Kingdom

Portfolio highlights

Encellin — Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.

Charles Farkas became an Advisory Partner at Bain & Company in July, 2015. Prior to that he was a Senior Partner in Bain & Company’s Boston office. He joined the firm in 1979 and was elected to the partnership in 1985. Mr. Farkas advises chief executives and senior managers in a wide variety of industries on issues critical to long-termsuccess. He has served as the global leader of Bain & Company’s Financial Services practice, the North American head of Bain’s Healthcare practice and as the Managing Director of Bain Canada.He has worked globally with companies in a wide range of industries including healthcare providers and suppliers, banking, insurance, brokerage, credit cards, consumer goods, retailing and industrial products.With over 36 years of experience, Mr. Farkas is highly sought out by clients for his experience with issues of growth, strategy, leadership and change. He is the author of the best-selling book Maximum Leadership (1996) and numerous articles published in the Harvard Business Review, Fortune, In Vivo and other publications. In 2008 Consulting Magazine named Mr. Farkas one of the Top 25 Global Consultants.

Investment focus

Genetics, Life Science, Biotechnology
Private Equity
United States

Portfolio highlights

Courtagen Life Sciences — Courtagen Life Sciences is a biotech company that provides proteomic and genomic products and services to the life sciences industry. The company delivers tools that enable researchers and clinicians to make better decisions regarding drug development and patient care. It was founded in 1999 and headquartered in Woburn, Massachusetts.

Jeff Raikes is the Co-founder of the Raikes Foundation.

Investment focus

Video, AgTech, Sports
Series A, Series C, Series D
United States

Portfolio highlights

Hudl — Hudl provides video review and performance analysis tools for sports teams and athletes at every level.
Epicrop Technologies — Revolutionary epigenetic technologies for crop enhancement producing increases in yield, resilience, and stress tolerance.

A pioneer of the venture capital industry in Canada, Haig co-founded Ventures West in 1968 and spent twenty-five years working to establish the venture capital industry in Canada. Since retiring from the firm he founded, Haig has become one of the most active and successful technology angel investors on theWest Coast. He has been instrumentalin the creation, growth, and success of dozens of technology companies and careers spanning four decades. Haig has served as co-founder, chair, and director of many high-profile companies, university and industry associations, and has been honoured by the Science Council of BC and the BC Technology Industries Association with awards for lifetime achievement and contribution to technology on Canada’s West Coast.

Investment focus

Life Science, Biotechnology, Bioinformatics
Pre-Seed
United States

Portfolio highlights

Epistemic AI — At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP.We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.We are creating a movement ofpeople enthusiastically committed to a new vision for the future of biomedical research and we hope you want to join us.

Noel Hall is the Director of Corporate of Wellcome Trust. He is a former Board Director, Co-founder, and President of Aspreva Pharmaceuticals Corp. He attended the University of London.

Investment focus

Biotechnology, Genetics, Life Science
Seed, Angel
Canada, United States

Portfolio highlights

Epistemic AI — At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP.We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.We are creating a movement ofpeople enthusiastically committed to a new vision for the future of biomedical research and we hope you want to join us.
Incisive Genetics — IG is focused on developing a cutting-edge non-viral delivery platform for genetic therapies. This disruptive and transformational delivery platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The Company's pre-clinical pipeline includes programs addressing neurologic and ocular geneticdiseases. IG is actively seeking partnerships with pharmaceutical companies developing gene therapies to be enabled by its novel delivery platform.

Avichal is Managing Partner at Electric Capital. He is a serial entrepreneur and technology executive. Avichal sold two companies and was most recently Director of Product at Facebook, which acquired his company Spool in 2012. He previously worked at Google on search ranking and ads ranking, is part-time at YCombinator, and an active angelinvestor.Avichal's firm, Electric Capital, focuses on cryptocurrencies that are rooted in technological utility. Electric performs deep technological diligence, such as compiling code, profiling nodes, and analyzing blockchains with in-house software. The founders of Electric have started and sold five companies, have been investing in cryptocurrencies since 2013, and are investors in Anchor, Bitwise, Chia, Coda, dYdX, Dfinity, Oasis, Thunder and many other crypto projects.

Investment focus

Software, Blockchain, Financial Services
Seed, Series A, Pre-Seed
United States, Canada, Mexico

Portfolio highlights

Key — Key provides a unique method to making significant professional relationships while also promoting career advancement, financial well-being, and work-life balance
Matic — The world's most advanced floor cleaner. Your home's best helper.
Magrathea — Magrathea Metals is a mining company that unlocks centuries of growth in human civilization by reducing the socioenvironmental impacts.

Haig Farris is one of Canada's best-known venture capitalists and experts in high-technology start-ups and turn-arounds, with a varied 30+ year history of involvement, commitment, and management. He has a law degree from the University of Pennsylvania. He is co-founder and former Executive Chair of the Board of Directors of D-Wave, and he isthe President of Fractal Capital, a private venture capital company financing high technology start-ups and resource service technology companies.Previously, Dr. Farris was a co-founder and partner of the Ventures West Management group of venture capital funds (1972-1990). In 2001, he received the British Columbia Technologies Industry Association's (BCTIA) Bill Thompson Award.He was awarded an Honorary Doctor of Laws degree from UBC in 1997 and named A Pioneer of Innovation by the Vancouver Board of Trade in 2001.

Investment focus

Biotechnology, Genetics, Life Science
Seed, Pre-Seed
Canada, United States

Portfolio highlights

Epistemic AI — At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP.We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.We are creating a movement ofpeople enthusiastically committed to a new vision for the future of biomedical research and we hope you want to join us.
Incisive Genetics — IG is focused on developing a cutting-edge non-viral delivery platform for genetic therapies. This disruptive and transformational delivery platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The Company's pre-clinical pipeline includes programs addressing neurologic and ocular geneticdiseases. IG is actively seeking partnerships with pharmaceutical companies developing gene therapies to be enabled by its novel delivery platform.

Joe Beverly

Investment focus

Marketing, Advertising, Life Science
Pre-Seed, Series A
United States

Portfolio highlights

MooveGuru — MooveGuru helps real estate agents and brokerages maintain relationships with clients from this move to the next.
Lena Biosciences — Lena Biosciences 3D cell culture products and services

Daniel Goldman Managing Partner of Ignition Angels/Keystone CatalystsA pioneer in online gaming and online communities, Daniel has a passion for applying technology to real world problems. He studied cognitive neuroscience at Columbia and became COO and VP PD at Posit Science, with Dr. Michael Merzenich, the world leading expert onneuroplasticity. There he incorporated the latest understanding of reward systems, neuroplasticity and the science of play into products for cognitive rehabilitation. Currently an angel investor, Daniel’s interest is for a world where everyone has ubiquitous access to opportunity, both social and economic, as well as freedom of thought.

Investment focus

Chemical, Biotechnology, Video
Seed, Series A, Convertible Note
United States, United Kingdom

Portfolio highlights

Chai — Chai allows anyone to detect anything, anywhere with DNA, transforming biotech into an everyday productivity tool. Chai's Real-Time PCR and qPCR instruments are as accurate as a lab test, but cost 10x less, and are easy enough for anyone to use. Chai also develops PCR Master Mixes for the detection any pathogen, bacteria, virus, allergen,gene, species, or DNA tracer on-site at the point of need.Chai is impacting large industries such as food, agriculture, research, education, and security, while providing new solutions to combat consumer fraud, protect the environment, improve global health, and make small businesses like microbrewers more profitable.
Grit Media — Grit is a sports media start-up creating original digital videos for Gen Z.
Advanced Ionics — Advanced Ionics has created an electrolyzer that allows industrial hydrogen users to produce green hydrogen for less than $1/kg.

Nimi Katragadda is an investor at BoxGroup, which is a seed stage venture fund that invests in entrepreneurs building companies with visions to create the next generation of category defining businesses. Prior to joining BoxGroup, Katragadda worked at Google and J.P. Morgan. She holds a MBA from Harvard Business School and a BA in Economics fromHarvard.

Investment focus

Life Science, Biotechnology
Seed, Pre-Seed, Series A
United States

Portfolio highlights

Ansa — The closed loop platform built for your customers.
Prime Discoveries — Prime Discoveries develops rapid, novel diagnostics for COVID (Omicron) that can help laboratories scale and test millions of samples.

Douglas B. Hansen is a co-founder of Redwood and served as Redwood’s President from 1994 through 2008. Mr. Hansen retired from his position as President of Redwood at the end of 2008. Mr. Hansen has been a director of Redwood since 1994. Mr. Hansen serves on the Board of Directors of Four Corners Property Trust, Inc., a publicly traded real estateinvestment trust. Mr. Hansen also serves on the board of River of Knowledge, a not-for-profit institution. Mr. Hansen holds a B.A. in Economics from Harvard College and an M.B.A. from Harvard Business School.

Investment focus

Analytics, Life Science, Biotechnology
Seed
United States

Portfolio highlights

Thrive Bioscience — Thrive Bioscience is commercializing a family of instruments and software that provide imaging, analytics, and automation to significantly improve cell culture and the analysis of live cells. Thrive’s instruments empower biologists to deliver consistent, reproducible results by leveraging microscopy, robotics, fluidics, and other fields, to captureimages and data and provide analysis, reports, guidance, documentation, and a database on the cells and on cell culture processes.

Dilek was actively investing as an angel and being an active chairwomen since 2017. She has been an angel investor in companies like Picus Security, DataRow (acquired by AWS), Genomize, and Genialis, having a board seat on multiple of them.Previously she was an investor at 212, an early-stage technology venture capital in İstanbul. She investedin companies like IyziCo, the biggest Fintech company in the region and Insider, global marketing automation software, funded by Sequoia Capital and so on.Prior to 212, Dilek worked at Groupon as Director of Strategy and Analysis, Management Consultant at Accenture and Business Developer at Koc Group. She started her career in the USA, where she held different project management positions and also started her own startup.Dilek received a BA honors degree in Mechanical Engineering from Yildiz Technical University and MBA from Johnson & Wales University, both with honor degrees. Dilek is also one of the first Kauffman Fellows, chosen from Turkey and distinguished by scholarship. She is also a founding member and leader of Arya Women Investment Platform. She is a guest lecturer at Stanford University and a judge at European Commission. Dilek was awarded as One of the Most Successful Women Leaders in Turkey, thanks to her contributions and impact on tech industry.Outside the office, Dilek loves to experience authenticity in new destinations. She is a competitive basketball player, a serious artwork collector, and an avid reader of books. She puts deliberate effort to spend quality time with her loving family and friends; informative pastry cooking sessions with her daughter, sophisticated board games while drinking coffee with relatives and friends, or book clubs to foster intellectual curiosity between friends and colleagues. She also jumps every morning to find the leaders of future who will be able to create big impact and help them at their journey. It is fascinating to witness how her life outside the office enriches her work as an investor.

Investment focus

Software, iOS, Transportation
Seed, Pre-Seed
United States, United Kingdom, Turkey

Portfolio highlights

Deplike — Everyone can make music!
liftOS — liftOS allows you to find, access and work with your SaaS tools without friction. Organise your data & apps and spend less time switching tabs.
Genialis — Genialis is a precision medicine data science company focused on new ways to treat disease. Blending computational biology and AI-based methods, Genialis merges and models data at the intersection of clinical and translational medicine and drug discovery. Genialis is trusted by biopharma and big pharma alike, to validate targets, predict biomarkersand optimally position novel drugs. Together, Genialis and its partners are bringing improved solutions to drug discovery to change people's lives.

Paul B. Manning has served as the chairman of our board of directors since December 2017 and as a member of our board of directors since December 2015. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies,which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of Dova Pharmaceuticals, Inc., a publicly traded pharmaceutical company, as well as various private companies. Mr. Manning was previously on the board of directors of Perrigo Corporation, Concordia Healthcare Corp. and AveXis, Inc. Mr. Manning received a B.S. in microbiology from the University of Massachusetts.

Investment focus

Biotechnology, Therapeutics, Medical
Series A, Series B, Post-IPO Equity
United States

Portfolio highlights

Kriya Therapeutics — Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.
Liquidia Technologies — Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.
The Paul and Diane Manning Institute of Biotechnology — The Paul and Diane Manning Institute of Biotechnology engages in the medical research that leads to new medical treatments, including cellular therapy, gene therapy, nanotechnology and drug delivery.

Jim Greer is the Chief Executive Officer at Bash. He was the co-founder and Chief Executive Officer of Kongregate. Before founding Kongregate in June 2006, Jim was Technical Director for Pogo at Electronic Arts. He has worked in the game industry since 1991.

Investment focus

Health Care, Life Science, Biotechnology
Seed
United States

Portfolio highlights

Vium — Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology,pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs.Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies.Vium was founded in 2013 and is headquartered in San Mateo, California, United States.

Bill is the Chairman and Co-Founder of the Pear Tree Funds, the President of Pear Tree Investment Advisors, Inc., and the Chairman of U.S. Boston Capital Corporation. He has over 40 years of experience in the finance and investment management business.Bill holds the Chartered Financial Analyst (CFA) designation and is a member of the CFAInstitute and the Boston Security Analysts Society. He obtained his JD from Harvard Law School, an LLM in taxation from Boston University School of Law, a Masters in Personnel Administration from George Washington University, and a BS with distinction from the United States Naval Academy in Annapolis, Maryland.

Investment focus

Analytics, Life Science, Biotechnology
Seed
United States

Portfolio highlights

Thrive Bioscience — Thrive Bioscience is commercializing a family of instruments and software that provide imaging, analytics, and automation to significantly improve cell culture and the analysis of live cells. Thrive’s instruments empower biologists to deliver consistent, reproducible results by leveraging microscopy, robotics, fluidics, and other fields, to captureimages and data and provide analysis, reports, guidance, documentation, and a database on the cells and on cell culture processes.

Timothy Springer is an internationally recognized leader in structural biology and immunology. With over 500 peer-reviewed publications that have received over 90,000 citations, he is one of the most highly cited scientists in any field. Timothy Springer received his Ph.D. from Harvard University in 1976, and subsequent post-doctoral training withDr. Cesar Milstein in Cambridge, UK. Timothy Springer has been elected to the National Academy of Sciences and to the American Academy of Arts and Sciences. Among numerous awards and honors, Timothy Springer is a recipient of the Royal Society of Medicine Medal, the William B. Coley Medal from the Cancer Research Institute, and the Crafoord Prize from the Swedish Academy of Sciences. Timothy Springer's research laid the foundation for a new class of pharmaceuticals, the selective adhesion molecule inhibitors, which include the approved drugs, alefacept, efalizumab, and natalizumab. Timothy Springer was the Founder of LeukoSite, a biotechnology company acquired by Millennium Pharmaceuticals in 1999. LeukoSite developed therapeutics for inflammatory, autoimmune, and cancer applications, including FDA-approved Campath™.

Investment focus

Biotechnology, Medical, Health Care
Series A, Series B, Seed
United States, Canada

Portfolio highlights

Prenuvo — Prenuvo offers MRI scanning systems that help in early detection of cancer and other diseases.
Seismic Therapeutic — Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases.
Tectonic Therapeutic — Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).

Scott Garber is the Managing Partner of Early Light Ventures. He attended The George Washington University School of Business.

Investment focus

Software, Information Technology, Cyber Security
Seed, Pre-Seed, Series A
United States

Portfolio highlights

Ethix360 — ETHIX360 provides Compliance as a Service (CaaS); a simple, affordable answer to employee ethics communication and human resources case management.
Ash & Erie — Men's clothes designed from scratch for shorter men 5'8" and under. Find men's casual and formal clothing from button-downs, t-shirts, sweaters, denim jeans, chinos, and more. FREE Shipping, Exchanges, and Returns.
Outlogic — Outlogic is a provider of location data for the retail, real estate, and financial markets. Outlogic has exemplified high standards and best practices for the collection and use of location data while still allowing companies to develop disruptive tools built on a foundation of quality data.

Leonardo DiCaprio is an American actor and film producer. He has been nominated for three Academy Awards and nine Golden Globe Awards. He won the Golden Globe Award for Best Actor for his performance in The Aviator (2004), and has been nominated by the Screen Actors Guild, Satellite Awards, and the British Academy of Film and Television Arts. Acommitted environmentalist, DiCaprio has received praise from environmental groups for his activism. At the 2007 Oscar ceremony, DiCaprio and former Vice President Al Gore announced that the Academy Awards had incorporated environmentally intelligent practices throughout the planning and production processes, and on July 7, 2007, DiCaprio presented at the American leg of Live Earth.

Investment focus

Food and Beverage, Food Processing, Health Care
Series A, Funding Round, Seed
United States, Israel, Switzerland

Portfolio highlights

Polestar — Wir stellen Performance-Elektroautos her. Unser Ziel: eine bessere Zukunft durch Innovationen.
ID Genève — We make watches that reflect the values and principles of people who are committed to fight climate change and who wish to have a positive social and environmental impact. The materials used are circular and have a lower carbon footprint than the industry average.
NUVIEW — Explore NUVIEW's LiDAR satellite technology, revolutionizing Earth observation with annual global mapping, unrivaled coverage, and cutting-edge data.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
SolasCure — Our proprietary technology leverages biomimicry and evidence-based medicine to treat patients with chronic wounds.
PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.

Julia is an advisor to start ups and an active technology angel investor, with angel investments in Gusto, Lever, Baobab Studios, Brit Media, BetterUp, SafeGraph, CodeFights, AltSchool, MissionU, Owlet, Philz Coffee, Tynker, Happiest Baby, Kite, MileIQ (acq by MSFT), Locu (acq by GoDaddy), Beme (acq by CNN), Alt12 (acq by Honest Co), Worklife (acqby Cisco) & Wheelz (acq by Turo), and later stage investments in Uber, Alibaba (IPO’d), FlipKart, Postmates, DocuSign, Survey Monkey, Blue Bottle Coffee, Stripe and Spotify.Julia began her career as a corporate attorney at Wilson Sonsini Goodrich Rosati. In 2006, Julia joined Facebook as the second attorney in the legal department and led the commercial transactions team from June 2006 until April 2011. She negotiated numerous deals strategic to Facebook's growth and development, including with Microsoft, Spotify, ABC/Disney, CNN and YouTube. Julia led a team of 9 attorneys, oversaw Facebook's legal work related to its international expansion and operations, and worked on matters related to product and IP law. In her five years at Facebook, Julia was instrumental in scaling the legal team from two people to 40, setting up departmental procedures and infrastructure and hiring and managing outside counsel. Julia received her JD from Harvard Law School in 1997, graduating cum laude, and her BA from UC Berkeley, graduating magna cum laude and phi beta kappa with a degree in Political Science. She is a member of the State Bar of California.In her free time, Julia volunteers at her kids' schools and with other community organizations. She has chaired the annual auctions at Bing Nursery School and Nueva School and is on the National Council of World Wildlife Fund. Previously, she sat on the boards of the Oshman Family JCC, Hebrew Free Loan Association and Hands on Bay Area. She biked from SF to LA with the California AIDS Ride and ran the Honolulu Marathon with Team in Training.

Investment focus

Software, Machine Learning, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, Canada, Colombia

Portfolio highlights

Celo — Celo is global payments infrastructure that makes financial tools accessible to anyone with a mobile phone
Dondo — Get what you want giving what you have
UploadVR — VR & AR news, reviews, guides, and industry analysis.

Elliott Sigal, M.D., Ph.D. joined NEA as a Venture Partner and Senior Advisor in 2014. He is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as Chief Scientific Officer and President of R&D for Bristol-Myers Squibb from 2004 until 2013. He was a principal architect of the successful Biopharma TransformationStrategy of the company. He has been instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative. Under his leadership, fourteen new medicines have come to market including Abilify (Schizophrenia, Bipolar Disorder), Reyataz (HIV/AIDS), Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Atripla (HIV/AIDS), Ixempra (Breast Cancer), Onglyza and Kombiglyze (Diabetes), Nulojix (Transplantation), Eliquis (Anticoagulant), Yervoy (Melanoma), and Forxiga (Diabetes). Among his accomplishments in various therapeutic areas was building BMS research into a lead position in the promising area of immuno-oncology. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence.Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. Dr. Sigal received his M.D. from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). Prior to medical school he studied engineering at Purdue University, where he received a B.S., M.S., and Ph.D. Dr. Sigal serves as a member of the Board of Directors for the Mead Johnson Nutrition Company and the Melanoma Research Alliance.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B
United States

Portfolio highlights

Surface Oncology — Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer.
Mersana Therapeutics — Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.

Investors by industry

FinTech

Consumer

Gaming

Media (entertainment)

EdTech

Artificial intelligence